Chromosome 8q as the most frequent target for amplification in early gastric carcinoma
Affiliations: Department of Biomedical Laboratory Science, Korea Nazarene University, Cheonan 330‑718, Republic of Korea
- Published online on: February 3, 2014 https://doi.org/10.3892/ol.2014.1849
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Early gastric carcinoma (GC) is considered to be a curable cancer, as it progresses to the advanced stage following varying durations. Understanding the early stage of GC may provide an insight into its pathogenesis and contribute to reducing the mortality rate of this disease. To investigate the genomic aberrations associated with 22 cases of early GC, high‑density microarray comparative genomic hybridization was performed in the present study. The most notable finding was copy number gains (log2 ratio >0.25) on the long arm of chromosome 8, which occurred in 77.3% (17/22) of GC cases, and the delineated minimal common region was 8q22.1‑q24.3. More specifically, two amplified (log2 ratio >1) loci in the 8q22.1‑q24.3 region were detected in 18.2% (4/22) of GC cases. The first loci covered a region of 102.4‑107.9 kb, mapping on 8q22.3‑q23.1, and comprised the transcription factor CP2‑like 3 gene. The second loci, spanning 128.7‑145.7 kb on 8q24.21‑q24.3, comprised the representative oncogene of myelocytomatosis. Furthermore, the following possible target genes that were not previously considered to play a pathogenic role in GC were identified: Plasmacytoma variant translocation 1, cysteine/histidine rich 1, kinesin family member C2, forkhead box H1, protein phosphatase 1 regulatory subunit 16A, glutamic‑pyruvate transaminase, LOC113655 and RecQ protein‑like 4. In the present study, previous findings showing that 8q mutations accumulate early during the multistage pathogenesis of GC were confirmed and expanded upon. The confirmation of previously reported 8q gains and the identification of novel target genes at 8q22.1‑q24.3 amplified chromosomal sites should aid in improving our understanding of the molecular mechanisms underlying the tumorigenesis of early GC.